Adamax

What it is

Adamax is built from Semax, a short peptide related to a fragment of ACTH, a natural hormone involved in the body's stress response. Semax was engineered decades ago to keep some of that fragment's effects on brain cells while dropping its hormonal activity. Adamax adds a further chemical group to that structure, intended to help the molecule cross into brain tissue and resist breakdown longer than Semax alone.

Because Adamax itself has almost no independent publication record, what is understood about this family of molecules comes from Semax research. That work has centred on two themes: how the peptide affects BDNF, a protein tied to brain-cell growth and connection-building, and how it affects the brain's own chemical messengers, particularly serotonin [2][3]. Some of the same research group's work has looked at recovery after stroke, though with real limits described below.

How it is studied

The studies behind this research area are done in rats, given Semax into the nose, plus a smaller number of human observations, mostly from Russian research groups, in patients recovering from stroke. Rat studies have measured brain BDNF protein and its receptor, TrkB, along with brain levels of serotonin and its breakdown products, after a single administration or a short course [2][3]. No placebo-controlled, independently replicated human trial of either Semax or Adamax has been published outside Russia.

What studies report

• In rats, a single administration of Semax raised BDNF protein and activated its receptor, TrkB, in the hippocampus, alongside changes in learning-related behaviour on a standard conditioning test. [2]
• In rats, Semax raised the turnover of serotonin in brain tissue, while its effect on dopamine only appeared when the animals were also given a stimulant drug, suggesting Semax modulates rather than directly drives that pathway. [3]
• Non-randomized clinical observations from Russian stroke units describe faster functional recovery and rising blood BDNF levels in patients given Semax alongside standard rehabilitation, though the studies were not blinded or placebo-controlled. [1]

What is not known

No study has tested Adamax, the modified compound itself, in either animals or people; every citation available concerns the unmodified parent peptide, Semax. Whether the added chemical group changes Adamax's effects, its safety, or how long it lasts in the body compared with Semax has not been independently measured. The human stroke research on Semax comes from a single country's research groups using designs that were not randomized or placebo-controlled, so it cannot rule out that other aspects of stroke care explain the reported improvements.

Reported adverse findings

• The Russian stroke observations did not describe serious adverse events tied to Semax, but these were not formal safety trials designed to systematically capture side effects. [1]

Regulatory status

Neither Adamax nor Semax is approved by the FDA or Health Canada. Semax is available as a prescribed medicine in Russia; that status does not extend to Adamax, which has not been reviewed by any medicines regulator.